SAN CARLOS, CA / ACCESS Newswire / October 8, 2026 / Marquis Who's Who is proud to interview and honor Anthony B. Chen, ...

This strategic implementation positions VERAXA ahead of the FDA's 2025 roadmap, which encourages the phased reduction and ultimate replacement of animal testing in favor of human-relevant, non-animal ...

UNE researcher Scott Wood’s startup, CellField Technologies, is one of 20 teams nationwide selected from more than 200 ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ...

JEDDAH: Researchers and physicians will examine how cell and gene therapies can be translated into clinical treatments at the Second Stem Cell Therapy Conference, hosted by Alfaisal University in ...

Vir Biotechnology appoints David Liu as EVP and CMO, leveraging his immuno-oncology and regulatory expertise for upcoming ...

Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming ...

Clearmind’s latest submission follows a series of recent activities involving the U.S. federal government. In April, the Company welcomed President Trump’s Executive Order, “Accelerating Medical ...

Advances FDA-Aligned Methods To Reduce Animal Testing. VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.

By Edward Dankwah, GNA Accra, Oct. 6, GNA – Dr Zanetor Agyeman-Rawlings, Minister of Environment, Science and Technology, ...

Ocugen appoints Jolanda Crombach as General Manager of its European affiliate to advance gene therapy programs for blindness diseases.